456 related articles for article (PubMed ID: 12954053)
21. ORL1 and opioid receptor preferences of nociceptin and dynorphin A analogues with Dmp substituted for N-terminal aromatic residues.
Sasaki Y; Kawano S; Kohara H; Watanabe H; Ambo A
Bioorg Med Chem; 2006 Apr; 14(7):2433-7. PubMed ID: 16321540
[TBL] [Abstract][Full Text] [Related]
22. Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the kappa-opioid receptor.
Przydzial MJ; Pogozheva ID; Bosse KE; Andrews SM; Tharp TA; Traynor JR; Mosberg HI
J Pept Res; 2005 Mar; 65(3):333-42. PubMed ID: 15787963
[TBL] [Abstract][Full Text] [Related]
23. Structure-activity relationships of dynorphin analogs substituted in positions 2 and 3.
Schlechtingen G; DeHaven RN; Daubert JD; Cassel J; Goodman M
Biopolymers; 2003; 71(1):71-6. PubMed ID: 12712501
[TBL] [Abstract][Full Text] [Related]
24. Alanine scan of the opioid peptide dynorphin B amide.
Joshi AA; Murray TF; Aldrich JV
Biopolymers; 2017 Sep; 108(5):. PubMed ID: 28464209
[TBL] [Abstract][Full Text] [Related]
25. Tetrapeptide derivatives of [D-Pen(2),D-Pen(5)]-enkephalin (DPDPE) lacking an N-terminal tyrosine residue are agonists at the mu-opioid receptor.
McFadyen IJ; Sobczyk-Kojiro K; Schaefer MJ; Ho JC; Omnaas JR; Mosberg HI; Traynor JR
J Pharmacol Exp Ther; 2000 Dec; 295(3):960-6. PubMed ID: 11082429
[TBL] [Abstract][Full Text] [Related]
26. Enkephalin analogues containing beta-naphthylalanine at the fourth position.
Mierke DF; Said-Nejad OE; Schiller PW; Goodman M
Biopolymers; 1990 Jan; 29(1):179-96. PubMed ID: 2158358
[TBL] [Abstract][Full Text] [Related]
27. Characterization of non-opioid [3H]dynorphin A-(1-13) binding sites in the rat heart.
Dumont M; Lemaire S
J Mol Cell Cardiol; 1993 Aug; 25(8):983-91. PubMed ID: 7903402
[TBL] [Abstract][Full Text] [Related]
28. Both dynorphin A(1-17) and [Des-Tyr1]dynorphin A(2-17) inhibit adenylyl cyclase activity in rat caudate putamen.
Claye LH; Unterwald EM; Ho A; Kreek MJ
J Pharmacol Exp Ther; 1996 Apr; 277(1):359-65. PubMed ID: 8613942
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and evaluation of derivatives of leucine enkephalin as potential affinity labels for delta opioid receptors.
Choi H; Murray TF; Aldrich JV
Biopolymers; 2003; 71(5):552-7. PubMed ID: 14635095
[TBL] [Abstract][Full Text] [Related]
30. Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling.
Erchegyi J; Waser B; Schaer JC; Cescato R; Brazeau JF; Rivier J; Reubi JC
J Med Chem; 2003 Dec; 46(26):5597-605. PubMed ID: 14667214
[TBL] [Abstract][Full Text] [Related]
31. Syntheses, opioid binding affinities, and potencies of dynorphin A analogues substituted in positions, 1, 6, 7, 8 and 10.
Kawasaki AM; Knapp RJ; Walton A; Wire WS; Zalewska T; Yamamura HI; Porreca F; Burks TF; Hruby VJ
Int J Pept Protein Res; 1993 Nov; 42(5):411-9. PubMed ID: 7906258
[TBL] [Abstract][Full Text] [Related]
32. Human growth hormone-releasing hormone hGHRH(1-29)-NH2: systematic structure-activity relationship studies.
Cervini LA; Donaldson CJ; Koerber SC; Vale WW; Rivier JE
J Med Chem; 1998 Feb; 41(5):717-27. PubMed ID: 9513600
[TBL] [Abstract][Full Text] [Related]
33. Design and synthesis of 1-aminocycloalkane-1-carboxylic acid-substituted deltorphin analogues: unique delta and mu opioid activity in modified peptides.
Breveglieri A; Guerrini R; Salvadori S; Bianchi C; Bryant SD; Attila M; Lazarus LH
J Med Chem; 1996 Feb; 39(3):773-80. PubMed ID: 8576920
[TBL] [Abstract][Full Text] [Related]
34. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
Cheng LL; Stoev S; Manning M; Derick S; Pena A; Mimoun MB; Guillon G
J Med Chem; 2004 Apr; 47(9):2375-88. PubMed ID: 15084136
[TBL] [Abstract][Full Text] [Related]
35. Direct influence of C-terminally substituted amino acids in the Dmt-Tic pharmacophore on delta-opioid receptor selectivity and antagonism.
Balboni G; Salvadori S; Guerrini R; Negri L; Giannini E; Bryant SD; Jinsmaa Y; Lazarus LH
J Med Chem; 2004 Jul; 47(16):4066-71. PubMed ID: 15267245
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis, and biological properties of highly potent cyclic dynorphin A analogues. Analogues cyclized between positions 5 and 11.
Meyer JP; Collins N; Lung FD; Davis P; Zalewska T; Porreca F; Yamamura HI; Hruby VJ
J Med Chem; 1994 Nov; 37(23):3910-7. PubMed ID: 7966152
[TBL] [Abstract][Full Text] [Related]
37. 10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors.
Zhang A; Xiong W; Bidlack JM; Hilbert JE; Knapp BI; Wentland MP; Neumeyer JL
J Med Chem; 2004 Jan; 47(1):165-74. PubMed ID: 14695830
[TBL] [Abstract][Full Text] [Related]
38. Interactions of dynorphin A and related peptides with cardiac ouabain binding sites.
Dumont M; Lemaire S
J Mol Cell Cardiol; 1996 Mar; 28(3):615-21. PubMed ID: 9011644
[TBL] [Abstract][Full Text] [Related]
39. Structure-Activity Relationships of the Peptide Kappa Opioid Receptor Antagonist Zyklophin.
Joshi AA; Murray TF; Aldrich JV
J Med Chem; 2015 Nov; 58(22):8783-95. PubMed ID: 26491810
[TBL] [Abstract][Full Text] [Related]
40. [2',6'-Dimethyltyrosine]dynorphin A(1-11)-NH2 analogues lacking an N-terminal amino group: potent and selective kappa opioid antagonists.
Lu Y; Nguyen TM; Weltrowska G; Berezowska I; Lemieux C; Chung NN; Schiller PW
J Med Chem; 2001 Sep; 44(19):3048-53. PubMed ID: 11543672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
